Clinical trial NCT02705482: A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Official title: A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Select Advanced Solid Tumors
Keywords: Advanced solid tumors
MEDI0562
durvalumab
tremelimumab
OX40
PD-L1
CTLA-4
immuno-oncology
Cancer
Lead sponsor: MedImmune LLC
Sponsor class: INDUSTRY
First posted: 2016-03-10
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.

Detailed description: This is a Phase 1 multicenter, open-label study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.

Eligibility criteria: Inclusion Criteria:

Subjects must meet all of the following criteria:

1. Written and signed informed consent.
2. Age ≥ 18 years at the time of study entry.
3. Subjects must have received and have progressed, are refractory, or are intolerant to standard therapy appropriate for the specific tumor type. Subjects should not have received more than 3 prior lines of systemic therapy for recurrent or metastatic.
4. Subjects in the dose-escalation phase, must have histologic documentation of advanced solid tumors, excluding primary CNS tumors and hematologic malignancies.
5. Subjects in the dose-expansion phase, must have recurrent or metastatic disease solid tumors according to treatment arm as specified in the protocol.
6. Subjects who have received prior therapy with regimens containing CTLA 4, PD L1, or PD 1 antagonists are permitted to enroll if additional protocol criteria are met.
7. Subjects must have at least 1 lesion that is measurable using RECIST guidelines.
8. Subjects must consent to provide archived tumor specimens for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, subjects must consent and undergo fresh tumor biopsy.
9. All subjects are encouraged to consent to and provide both pretreatment and on treatment tumor biopsies.
10. ECOG Performance score of 0 or 1, unless protocol exceptions are met.
11. In the opinion of the investigator likely to complete ≥ 8 weeks of treatment.
12. Adequate hematologic, renal and hepatic function as determined by blood laboratory values.
13. At the time of Day 1 of the study, subjects with CNS metastases must have been treated and must be asymptomatic and meet the following:

    1. No concurrent treatment, inclusive of, but not limited to surgery, radiation, and/or corticosteroids
    2. At least 42 days without progression of CNS metastases as evidenced by magnetic resonance imaging (MRI) or computed tomography (CT) after last day of treatment
    3. At least 14 days since last dose of corticosteroids Note: Subjects with leptomeningeal disease or cord compression are excluded from the study.
14. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception from screening, and must agree to continue using such precautions for 180 days after the final dose of investigational product.
15. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use male condom plus, if locally available, spermicide from Day 1 and for 180 days after receipt of the final dose of investigational product.

Exclusion Criteria:

Any of the following would exclude the subject from participation in the study:

1. Prior treatment with TNFRSF agonists
2. Prior treatment with IMT for certain disease types may be restricted per protocol.
3. History of severe allergic reactions to any unknown allergens or any components of the study drug formulations
4. Active or prior documented autoimmune disease within the past 2 years.
5. Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow up period of an interventional study
6. Receipt of any conventional or investigational anticancer therapy not otherwise specified above within 28 days prior to the first dose
7. Any concurrent chemotherapy, IMT, or biologic or hormonal therapy for cancer treatment.
8. Unresolved toxicities from prior anticancer therapy.
9. Systemic therapeutic anticoagulation or daily aspirin dose exceeding 325 mg/per day.
10. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of MEDI0562 with exceptions as per protocol.
11. History of primary immunodeficiency, solid organ transplantation, or tuberculosis
12. Test results indicating active infection with human immunodeficiency virus (HIV) or hepatitis B or C defined by positive serologic testing and confirmatory viral nucleic acid testing
13. Pregnant or breastfeeding women
14. Major surgery within 4 weeks prior to first dose of MEDI0562 or still recovering from prior surgery.
15. Other invasive malignancy within 2 years with the exception of protocol specified criteria
16. Any uncontrolled intercurent illness or condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

Primary outcomes:
measure: Safety as defined by the presence of adverse events (AE), serious adverse events (SAE), and dose limiting toxicities (DLT).
timeFrame: From time of informed consent through 12 weeks after ending treatment with investigational product
Secondary outcomes:
measure: Preliminary Antitumor Activity:Best Overall Response
timeFrame: At approximately 3 time points through Day 113.
measure: Pharmacokinetics of MEDI0562/durvalumab or MEDI0562/tremelimumab: Cmax
timeFrame: To be assessed at approximately 12 clinic visits through Day 113
measure: Immunogenicity
timeFrame: At approximately 8 time points through Day 113.
measure: Pharmacodynamic Activity
timeFrame: At approximately 12 time points through Day 113.
measure: Preliminary Antitumor Activity: Disease Control
timeFrame: At approximately 3 time points through Day 113.
measure: Preliminary Antitumor Activity: Duration of Response
timeFrame: At approximately 3 time points through Day 113.
measure: Preliminary Antitumor Activity: Progression-free Survival
timeFrame: At approximately 3 time points through Day 113.
measure: Preliminary Antitumor Activity: Overall Survival
timeFrame: At approximately 3 time points through Day 113.
measure: Pharmacokinetics of MEDI0562/durvalumab or MEDI0562/tremelimumab: AUC
timeFrame: To be assessed at approximately 12 clinic visits through Day 113
measure: Pharmacokinetics of MEDI0562/durvalumab or MEDI0562/tremelimumab: Clearance
timeFrame: To be assessed at approximately 12 clinic visits through Day 113
measure: Pharmacokinetics of MEDI0562/durvalumab or MEDI0562/tremelimumab: t½
timeFrame: To be assessed at approximately 12 clinic visits through Day 113
measure: Preliminary Antitumor Activity: Objective Response
timeFrame: At approximately 3 time points through Day 113.
measure: Preliminary Antitumor Activity: Time to Response
timeFrame: At approximately 3 time points through Day 113.
measure: Preliminary Antitumor Activity: Percent Change from Baseline
timeFrame: At approximately 3 time points through Day 113.
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Research Site
state: California
city: Chicago
country: United States
facility: Research Site
state: Illinois
city: Saint Louis
country: United States
facility: Research Site
state: Missouri
city: Albuquerque
country: United States
facility: Research Site
state: New Mexico
city: New York
country: United States
facility: Research Site
state: New York
city: Huntersville
country: United States
facility: Research Site
state: North Carolina
city: Portland
country: United States
facility: Research Site
state: Oregon
city: Nashville
country: United States
facility: Research Site
state: Tennessee
city: Houston
country: United States
facility: Research Site
state: Texas
city: Villejuif
country: France
facility: Research Site
city: Amsterdam
country: Netherlands
facility: Research Site
city: Amsterdam
country: Netherlands
facility: Research Site
Study officials:
References:
citation: Goldman JW, Piha-Paul SA, Curti B, Pedersen KS, Bauer TM, Groenland SL, Carvajal RD, Chhaya V, Kirby G, McGlinchey K, Hammond SA, Streicher K, Townsley DM, Chae YK, Voortman J, Marabelle A, Powderly J. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Sep 1;28(17):3709-3719. doi: 10.1158/1078-0432.CCR-21-3016.